NASDAQ:GRFS - Grifols Stock Price, Price Target & More

Get Started

$22.14 -0.25 (-1.12 %)

(As of 05/27/2018 01:33 AM ET)

Previous Close$22.14

Today's Range$21.60 - $22.19

52-Week Range$19.92 - $25.18

Volume357,038 shs

Average Volume743,114 shs

Market Capitalization$15.29 billion

P/E Ratio20.13

Dividend Yield1.27%

Beta1.19

About Grifols (NASDAQ:GRFS)

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:GRFS

CUSIPN/A

Webwww.grifols.com

Phone34-93-571-2200

Debt

Debt-to-Equity Ratio1.62

Current Ratio3.01

Quick Ratio1.35

Price-To-Earnings

Trailing P/E Ratio20.13

Forward P/E Ratio16.90

P/E Growth1.46

Sales & Book Value

Annual Sales$4.88 billion

Price / Sales3.10

Cash Flow$1.4330 per share

Price / Cash15.45

Book Value$6.02 per share

Price / Book3.68

Profitability

EPS (Most Recent Fiscal Year)$1.10

Net Income$749.04 million

Net Margins15.46%

Return on Equity18.53%

Return on Assets6.07%

Miscellaneous

Employees14,877

Outstanding Shares682,820,000

Grifols (NASDAQ:GRFS) Frequently Asked Questions

What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

When did Grifols' stock split? How did Grifols' stock split work?

Grifols shares split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were issued to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of Grifols stock prior to the split would have 200 shares after the split.

How were Grifols' earnings last quarter?

Grifols (NASDAQ:GRFS) released its earnings results on Wednesday, February, 28th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by $0.03. The biotechnology company earned $1.26 billion during the quarter, compared to analyst estimates of $1.29 billion. Grifols had a return on equity of 18.53% and a net margin of 15.46%. View Grifols' Earnings History.

What price target have analysts set for GRFS?

6 brokerages have issued 1-year price objectives for Grifols' stock. Their predictions range from $22.00 to $22.00. On average, they anticipate Grifols' stock price to reach $22.00 in the next twelve months. View Analyst Ratings for Grifols.

Who are some of Grifols' key competitors?

Some companies that are related to Grifols include Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron (REGN), Takeda Pharmaceutical (TKPYY), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF) and Ono Pharmaceutical (OPHLF).

Who are Grifols' key executives?

Grifols' management team includes the folowing people:

Mr. Raimon Grifols Roura, Co-Chief Exec. Officer & Exec. Director (Age 54)
Mr. Ramón Riera Roca, COO, Chief Commercial Officer & Exec. Director (Age 63)
Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 62)
Mr. Víctor Grifols Deu, Co-CEO & Exec. Director (Age 41)
Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 60)

Has Grifols been receiving favorable news coverage?

Media coverage about GRFS stock has trended positive recently, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Grifols earned a news sentiment score of 0.31 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Grifols' major shareholders?

Grifols' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include AKO Capital LLP (1.71%), FIL Ltd (0.82%), Natixis (0.44%), Vaughan Nelson Investment Management L.P. (0.42%), Engadine Partners LLP (0.36%) and Artisan Partners Limited Partnership (0.34%). View Institutional Ownership Trends for Grifols.

Which institutional investors are selling Grifols stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Farallon Capital Management LLC, JPMorgan Chase & Co., New York State Common Retirement Fund, Sei Investments Co., BlackRock Inc., Van ECK Associates Corp and Envestnet Asset Management Inc.. View Insider Buying and Selling for Grifols.

Which institutional investors are buying Grifols stock?

GRFS stock was bought by a variety of institutional investors in the last quarter, including Natixis, FIL Ltd, Engadine Partners LLP, AKO Capital LLP, Millennium Management LLC, United Capital Financial Advisers LLC, Jane Street Group LLC and Thornburg Investment Management Inc.. View Insider Buying and Selling for Grifols.

How do I buy shares of Grifols?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $22.14.

How big of a company is Grifols?

Grifols has a market capitalization of $15.29 billion and generates $4.88 billion in revenue each year. The biotechnology company earns $749.04 million in net income (profit) each year or $1.10 on an earnings per share basis. Grifols employs 14,877 workers across the globe.

How can I contact Grifols?

Grifols' mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]

MarketBeat Community Rating for Grifols (GRFS)

Community Ranking:		2.1 out of 5 ( )
Outperform Votes:		158 (Vote Outperform)
Underperform Votes:		219 (Vote Underperform)
Total Votes:		377

MarketBeat's community ratings are surveys of what our community members think about Grifols and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Grifols (NASDAQ:GRFS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Grifols in the last 12 months. Their average twelve-month price target is $22.00, suggesting that the stock has a possible downside of 0.63%. The high price target for GRFS is $22.00 and the low price target for GRFS is $22.00. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Buy
Consensus Rating Score:	2.17	2.17	2.60	2.60
Ratings Breakdown:	1 Sell Rating(s) 3 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$22.00	$22.00	N/A	N/A
Price Target Upside:	0.63% downside	2.18% upside	N/A	N/A

Grifols (NASDAQ:GRFS) Consensus Price Target History

Price Target History for Grifols (NASDAQ:GRFS)

Grifols (NASDAQ:GRFS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/14/2018	HSBC	Upgrade	Reduce ➝ Hold		Low
3/1/2018	Morgan Stanley	Lower Price Target	Underweight ➝ Underweight	$23.00 ➝ $22.00	Medium
11/24/2017	UBS	Downgrade	Outperform ➝ Market Perform		N/A
10/31/2017	Citigroup	Initiated Coverage	Buy ➝ Buy		N/A
7/4/2017	Bank of America	Reiterated Rating	Buy		Medium
6/30/2017	Goldman Sachs Group	Downgrade	Buy ➝ Neutral		Low
3/30/2017	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight		High

(Data available from 5/27/2016 forward)

Grifols (NASDAQ:GRFS) Earnings History and Estimates Chart

Earnings by Quarter for Grifols (NASDAQ:GRFS)

Grifols (NASDAQ:GRFS) Earnings Estimates

2018 EPS Consensus Estimate: $1.27

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.29	$0.29	$0.29
Q2 2018	1	$0.33	$0.33	$0.33
Q3 2018	1	$0.31	$0.31	$0.31
Q4 2018	1	$0.34	$0.34	$0.34

Grifols (NASDAQ GRFS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/28/2018	Q4 2017	$0.31	$0.28	$1.2933 billion	$1.2576 billion	View	N/A
11/2/2017	Q3 2017	$0.29	$0.29		$1.2430 billion	View	N/A
7/28/2017	Q2 2017	$0.28	$0.27	$1.1898 billion	$1.2435 billion	View	N/A
5/3/2017	Q1 2017	$0.27	$0.26	$1.1438 billion	$1.1309 billion	View	N/A
2/28/2017	Q4 2016		$0.26		$1.1857 billion	View	N/A
11/8/2016	Q3 2016		$0.28		$1.1159 billion	View	N/A
7/28/2016	Q2 2016	$0.27	$0.27	$1.1884 billion	$1.1212 billion	View	N/A
5/5/2016	Q1 2016	$0.24	$0.22	$1.0408 billion	$1.0579 billion	View	N/A
11/4/2015	Q3 2015	$0.22	$0.23	$1.0051 billion	$1.0806 billion	View	N/A
7/30/2015	Q2 2015	$0.23	$0.22		$1.0974 billion	View	N/A
5/7/2015	Q1 2015	$0.24	$0.25	$972.80 million	$1.0225 billion	View	N/A
2/26/2015	Q4 2014	$0.29	$0.27		$1.0413 billion	View	N/A
10/31/2014	Q3 2014	$0.26	$0.22	$1.0360 billion	$1.0978 billion	View	N/A
7/30/2014	Q2 2014	$0.28	$0.20	$1.1565 billion	$1.0864 billion	View	N/A
5/6/2014	Q1 2014	$0.28	$0.25		$1.1113 billion	View	N/A
2/20/2014	Q4 2013		$0.15		$923.39 million	View	N/A
11/5/2013	Q3 2013		$0.17		$881.88 million	View	N/A
7/31/2013	Q2 2013		$0.18		$924.58 million	View	N/A
5/2/2013	Q1 2013		$0.18		$903.10 million	View	N/A
2/28/2013	Q4 2012		$0.10			View	N/A
10/30/2012	Q3 2012		$0.12			View	N/A
7/31/2012	Q2 2012		$0.11			View	N/A
5/11/2012	Q1 2012		$0.15			View	N/A
2/28/2012	Q4 2011		$0.05			View	N/A
11/14/2011	Q3 2011		$0.08			View	N/A

(Earnings results data provided by Zacks Investment Research)

Grifols (NASDAQ:GRFS) Dividend Information

Grifols pays an annual dividend of $0.28 per share, with a dividend yield of 1.26%. GRFS's most recent semiannual dividend payment was Thursday, June 8. Grifols pays out 25.45% of its earnings out as a dividend.

Most Recent Dividend:	6/8/2017
Annual Dividend:	$0.28
Dividend Yield:	1.26%
Payout Ratio(s):	25.45% (Trailing 12 Months of Earnings) 21.37% (Based on This Year's Estimates) 18.92% (Based on Next Year's Estimates) 19.54% (Based on Cash Flow)

Dividend Payments by Quarter for Grifols (NASDAQ:GRFS)

Grifols (NASDAQ:GRFS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/26/2017	semiannual	$0.1220	1.54%	5/30/2017	6/1/2017	6/8/2017
11/22/2016		$0.1530		12/5/2016	12/7/2016	12/7/2016
5/31/2016		$0.11		6/2/2016	6/6/2016	6/6/2016
12/1/2015		$0.2980		12/10/2015	12/14/2015	12/14/2015

(Data available from 1/1/2013 forward)

Grifols (NASDAQ GRFS) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 21.62%

Insider Trading History for Grifols (NASDAQ:GRFS)

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Grifols (NASDAQ GRFS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Grifols (NASDAQ GRFS) News Headlines

Source:

Date	Headline
	Grifols (GRFS) Upgraded to Hold at BidaskClub www.americanbankingnews.com - May 15 at 10:14 AM
	Grifols (GRFS) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - May 15 at 3:44 AM
	BRIEF-Grifols Expands Its Blood Typing Solutions Portfolio In US With Antisera Reagents www.reuters.com - May 14 at 9:36 AM
	Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents finance.yahoo.com - May 14 at 9:36 AM
	BRIEF-Boya Bio-Pharmaceutical Signs Agreement With Grifols S.A. To Set Up Blood Plasma Stations finance.yahoo.com - May 10 at 9:10 AM
	Grifols (GRFS) Upgraded to "Sell" at BidaskClub www.americanbankingnews.com - May 10 at 12:37 AM
	Grifols (GRFS) Downgraded by Zacks Investment Research to "Sell" www.americanbankingnews.com - May 9 at 7:31 PM
	Plasma Protein Therapeutics Market to touch US$31.8 bn by 2024, Says TMR globenewswire.com - May 8 at 9:00 AM
	BRIEF-Grifols Q1 EBITDA Down 2.8 Pct At 297 Mln Euros YoY www.reuters.com - May 3 at 8:58 AM
	Grifols (GRFS) Upgraded at Zacks Investment Research www.americanbankingnews.com - May 2 at 9:38 AM
	Grifols, Novo expansions prompt $1.3M renovation of JoCo training center finance.yahoo.com - April 27 at 4:46 PM
	Global Blood Plasma Market Analysis & Outlook 2018-2022 with Shire, CSL, Grifols, and Octapharma Dominating the ... www.businesswire.com - April 27 at 9:30 AM
	Grifols (GRFS) Downgraded by BidaskClub www.americanbankingnews.com - April 26 at 1:10 PM
	Grifols (GRFS) Downgraded by Zacks Investment Research to Hold www.americanbankingnews.com - April 25 at 11:36 AM
	Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer's Disease www.prnewswire.com - April 25 at 9:03 AM
	Form 6-K Grifols SA For: Apr 20 www.streetinsider.com - April 20 at 9:10 AM
	Grifols (GRFS) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - April 20 at 3:30 AM
	Zacks Investment Research Downgrades Grifols (GRFS) to Hold www.americanbankingnews.com - April 20 at 12:58 AM
	Grifols (GRFS) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 19 at 10:12 PM
	Grifols' (GRFS) "Buy" Rating Reaffirmed at Bank of America www.americanbankingnews.com - April 19 at 10:12 PM
	Grifols (GRFS) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 18 at 10:41 AM
	With 21.50% Earnings Growth, Did Grifols SA. (BME:GRF) Outperform The Industry? finance.yahoo.com - April 13 at 9:18 AM
	Now Could Be The Right Time To Buy Grifols With Worries Over Trade With China seekingalpha.com - April 10 at 4:51 PM
	Report: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, Shenandoah Telecommunications, Grifols, S.A, and Orthofix International N.V — New Horizons, Emerging Trends, and Upcoming Developments finance.yahoo.com - April 10 at 9:24 AM
	Zacks Investment Research Downgrades Grifols SA, Barcelona (GRFS) to Hold www.americanbankingnews.com - April 7 at 2:46 PM
	Grifols 2017 Annual Report on Form 20-F filed with the SEC on April 6, 2018 finance.yahoo.com - April 6 at 5:02 PM
	Citigroup Begins Coverage on Grifols SA, Barcelona (GRFS) www.americanbankingnews.com - April 2 at 9:13 PM
	Grifols SA, Barcelona (GRFS) Upgraded to Buy by BidaskClub www.americanbankingnews.com - March 29 at 4:10 PM
	Estimating The Fair Value Of Grifols SA. (BME:GRF) finance.yahoo.com - March 29 at 9:20 AM
	Grifols SA, Barcelona (GRFS) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - March 26 at 3:06 AM
	Grifols SA, Barcelona (GRFS) Upgraded to Buy at ValuEngine www.americanbankingnews.com - March 25 at 5:52 PM
	Grifols SA, Barcelona (GRFS) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - March 24 at 8:23 PM
	Grifols SA, Barcelona (GRFS) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - March 24 at 12:16 PM
	Grifols SA, Barcelona (GRFS) Upgraded to "Buy" by Zacks Investment Research www.americanbankingnews.com - March 23 at 12:30 AM
	Is It Time To Buy Grifols SA. (BME:GRF) Based Off Its PE Ratio? finance.yahoo.com - March 22 at 9:15 AM
	Can Grifols SA. (BME:GRF) Continue To Outperform Its Industry? finance.yahoo.com - March 15 at 8:55 AM
	Critical Review: Grifols SA, Barcelona (GRFS) & SIGA Technologies (SIGA) www.americanbankingnews.com - March 15 at 1:05 AM
	Grifols SA, Barcelona (GRFS) Lifted to "Hold" at HSBC www.americanbankingnews.com - March 14 at 9:02 PM
	Grifols breaks ground on $120M Clayton facility finance.yahoo.com - March 14 at 6:13 PM
	Consolidated Research: 2018 Summary Expectations for B Communications, Student Transportation, Aurinia Pharmaceuticals, Grifols, S.A., NEXEO SOLUTIONS, and ASML Holding N.V. — Fundamental Analysis, Key Performance Indications finance.yahoo.com - March 13 at 9:14 AM
	Grifols SA, Barcelona (GRFS) Holdings Boosted by Alliancebernstein L.P. www.americanbankingnews.com - March 6 at 4:14 AM
	BRIEF-Grifols Announces New Agreement With Henry Schein To Distribute Normal Saline Solution In U.S. www.reuters.com - March 5 at 5:20 PM
	Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S. finance.yahoo.com - March 5 at 9:07 AM
	Grifols SA, Barcelona (GRFS) Shares Sold by Arrowstreet Capital Limited Partnership www.americanbankingnews.com - March 5 at 4:42 AM
	Grifols SA, Barcelona (GRFS) PT Lowered to $22.00 www.americanbankingnews.com - March 1 at 6:56 PM
	Grifols SA, Barcelona (GRFS) Given Average Recommendation of "Hold" by Analysts www.americanbankingnews.com - March 1 at 3:34 AM
	Grifols Shines Light on Rare Disease with Launch of Educational Campaign "Look Into Genetic COPD" finance.yahoo.com - February 28 at 5:22 PM
	Citadel Advisors LLC Reduces Position in Grifols SA, Barcelona (GRFS) www.americanbankingnews.com - February 28 at 10:52 AM
	FDx Advisors Inc. Acquires 2,558 Shares of Grifols SA, Barcelona (GRFS) www.americanbankingnews.com - February 27 at 12:46 PM
	Sei Investments Co. Has $10.94 Million Stake in Grifols SA, Barcelona (GRFS) www.americanbankingnews.com - February 25 at 6:56 AM

Grifols (NASDAQ:GRFS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Grifols (NASDAQ:GRFS) Income Statement, Balance Sheet and Cash Flow Statement

Grifols (NASDAQ GRFS) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff